conditions at a temperature greater than 25°C below the melting temperature of a perfectly base-paired double-stranded DNA to a molecule with Sequence ID No. 3.

14. (twice amended) [The] An isolated nucleic acid molecule [of claim 13] encoding a scavenger receptor protein having the sequence of Sequence ID No. 3 [or a degenerate variant thereof].

15. (twice amended) [The] An isolated nucleic acid molecule [of claim 11] encoding a protein with the amino acid sequence shown in Sequence ID No. 4.

21. (three times amended) [A nucleic acid molecule] An expression vector comprising the molecule of claim 11 encoding the scavenger receptor protein [and an expression vector].

22. (three times amended) A [composition comprising a] host cell [suitable for expression of a scavenger receptor wherein the host cell comprises] comprising the nucleic acid molecule of claim [21] 11.

44. (twice amended) A method for screening for a compound which alters the binding of scavenger receptor protein type BI, which is encoded by a nucleotide molecule hybridizing to SEQ ID Nos. 3 and 7 under moderately stringent hybridization conditions at a temperature of approximately 25°C below the melting temperature of a perfectly base-paired double-stranded DNA and which selectively binds to low density lipoprotein and to modified lipoprotein having the characteristics of acetylated low density lipoprotein in cell medium containing 10% serum, comprising

providing reagents for use in an assay for binding of low density lipoprotein or modified low density lipoprotein to the scavenger receptor protein the reagents comprising SR-BI, low

density lipoprotein or modified low density lipoprotein, and means for determining if the low density lipoprotein or modified low density lipoprotein is bound to the scavenger receptor protein,

adding the compound to be tested to the assay, and

determining if the amount of modified low density lipoprotein or low density lipoprotein which is bound to the scavenger receptor protein is altered as compared to binding in the absence of the compound to be tested.

48. (twice amended) A method for removing low density lipoprotein from patient blood comprising reacting the blood with immobilized scavenger receptor protein type B, wherein the scavenger receptor protein type BI is encoded by a nucleotide molecule hybridizing to SEQ ID Nos. 3 and 7 under moderately stringent hybridization conditions at a temperature of approximately 25°C below the melting temperature of a perfectly base-paired double-stranded DNA and selectively binds to low density lipoprotein and to modified lipoprotein having the characteristics of acetylated low density lipoprotein in cell medium containing 10% serum, under conditions wherein the low density lipoprotein is bound to the scavenger receptor.

49. (twice amended) A method for inhibiting uptake of lipoprotein or lipids by adipocytes comprising

administering a compound selectively inhibiting binding of lipoprotein to the scavenger receptor protein type BI, wherein the scavenger receptor protein type BI is encoded by a nucleotide molecule hybridizing to SEQ ID Nos. 3 and 7 and selectively binds to low density lipoprotein and to modified lipoprotein having the characteristics of acetylated low density

lipoprotein, under conditions wherein the low density lipoprotein is bound to the scavenger receptor.

50. (amended) A method for screening patients for abnormal scavenger receptor protein activity or function comprising

determining the presence of scavenger receptor protein type BI, wherein the scavenger receptor protein type BI is encoded by a nucleotide molecule hybridizing to SEQ ID Nos. 3 and 7 under moderately stringent hybridization conditions at a temperature of approximately 25°C below the melting temperature of a perfectly base-paired double-stranded DNA and selectively binds to low density lipoprotein and to modified lipoprotein having the characteristics of acetylated low density lipoprotein, and

determining if the quantity present or the function of the receptor is equivalent to that present in normal cells.

Remarks

Information Disclosure Statement

An Information Disclosure Statement with copies of all cited references and payment of the fee for filing after issuance of an office action was mailed in this case on March 29, 2002. The postcard indicated receipt by the U.S. Patent Office on April 11, 2002.

Consideration of the Information Disclosure Statement and initialing of the PTO 1449 is requested.

Restriction Requirement

This application claims priority to June 23, 1994. It therefore does not qualify under 37